Effects of Salvinorin A in Healthy Controls

Psychotomimetic Effects of Kappa Opioid Receptor Agonist Salvinorin A in Healthy Controls

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00700596

Enrollment

105

Registered

2008-06-18

Start date

2009-02-12

Completion date

2014-08-22

Last updated

2022-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Salvia, SA, Salvinorin, Psychotomimetic Effects

Brief summary

This study evaluates the effects of Salvinorin A (SA). SA is the active ingredient of the plant Salvia divinorum that is known to have been used by Mexican Indians as part of religious rituals. The purpose of this project is to understand what people experience when they consume Salvinorin A.

Interventions

DRUGSalvinorin A

Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg

DRUGPlacebo

Control or Placebo SA (30 % ethanolic solution)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

-Previous exposure to inhaled Salvinorin A (SA).

Design outcomes

Primary

Measure	Time frame
Positive and Negative Syndrome Scale, Clinician Administered Dissociative Symptoms Scale, Visual Analog Scale, Assessment of Opioid Effects, Cognitive Testing	Time Frame: -30, +10, +30, +90, +120. +200

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026